GE HealthCare Technologies (GEHC) Q3 2026 earnings summary

Executive summary

• Q3 revenue grew 7.2% reported and 6.2% organically, with growth across all segments; adjusted EBIT margin expanded 180 bps and FY2026 guidance was raised.

• Commercial execution, Heartbeat operating practices and customer adoption of new products supported results.

Financial highlights

• Revenue was $5.513B; operating income was $805M versus $653M, and net income attributable was $615M versus $446M.

• Adjusted EBIT rose 19.9% to $913M; adjusted EBIT margin increased 180 bps to 16.6%.

• Adjusted EPS was $1.34 versus $1.07; diluted EPS was $1.36 versus $0.98.

• Free cash flow was $793M versus $483M; operating cash flow was $907M versus $593M.

Outlook and guidance

• FY2026 organic revenue growth guidance rose to 4.0%-5.0% from 3.0%-4.0%; adjusted EBIT margin guidance is 15.5%-15.7%.

• Adjusted EPS guidance rose to $4.95-$5.05 from $4.80-$5.00; free cash flow guidance increased to $1.6B+ from $1.5B-$1.6B.

• Adjusted effective tax rate guidance was reaffirmed at 20.0%-21.0%.